Glaukos (NYSE:GKOS) posted second-quarter results today that beat the overall consensus on Wall Street.
The San Clemente, Calif.-based company reported losses of -$17.5 million, or -38¢ per share, on sales of $78.1 million for the three months ended June 30 for a sales growth of 147.46% compared with Q2 2020.
Adjusted to exclude one-time items, earnings per share were -11¢, 18¢ ahead of The Street, where analysts were looking for sales of $71.4 million.
“We are pleased with our record second-quarter financial performance driven by sound execution on our key strategic priorities and the ongoing market recovery,” president and CEO Thomas Burns said in a news release. “We remain steadfastly dedicated to transforming the treatment of chronic eye diseases for the benefit of patients worldwide.”
Glaukos said it expects revenues for the fiscal year 2021 to be in the range of $285 million to $290 million.
Shares in GKOS were down -4.43% to $48.70 apiece at market open.
